导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.61% | 1570/4773 |
| 近一周 | -1.48% | 469/5462 |
| 近一月 | 0.59% | 538/5421 |
| 近一季 | -2.62% | 1276/5209 |
| 近半年 | -12.87% | 3805/4920 |
| 近一年 | 9.99% | 1040/4366 |
| 近两年 | 41.10% | 1838/2954 |
| 近三年 | 25.03% | 1277/2253 |
| 成立以来 | 75.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.79% 103/4961 |
-5.67% 3605/5312 |
- - |
- - |
| 2025 | 15.12% 2571/4813 |
-2.14% 2848/3635 |
1.38% 2359/4076 |
9.40% 3359/4524 |
6.06% 382/4813 |
| 2024 | 14.23% 1068/3463 |
6.93% 270/2808 |
0.96% 521/3014 |
9.28% 2707/3129 |
-3.18% 2283/3463 |
| 2023 | -0.88% 477/2656 |
12.14% 314/2280 |
0.64% 294/2385 |
-5.46% 1324/2515 |
-7.09% 2048/2655 |
| 2022 | -14.03% 355/2207 |
-8.05% 268/1919 |
4.11% 1057/2016 |
-11.85% 597/2113 |
1.87% 1106/2208 |
| 2021 | 12.52% 380/1822 |
4.26% 152/1255 |
4.11% 921/1330 |
5.31% 280/1466 |
-1.57% 1373/1822 |
| 2020 | 18.04% 750/1250 |
-5.11% 399/1028 |
0.14% 1008/1067 |
11.91% 416/1164 |
11.00% 570/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 富国中证国企一带一路ETF联接C VS. 长安沪深300非周期A(740101) |